Cargando…
Upregulated PARP1 confers breast cancer resistance to CDK4/6 inhibitors via YB-1 phosphorylation
BACKGROUND: Cyclic-dependent kinase (CDK) 4/6 kinases, as the critical drivers of the cell cycle, are involved in the tumor progression of various malignancies. Pharmacologic inhibitors of CDK4/6 have shown significant clinical prospects in treating hormone receptor-positive and human epidermal grow...
Autores principales: | Quan, Chuntao, Wu, Zhijie, Xiong, Juan, Li, Manqing, Fu, Yu, Su, Jiaying, Wang, Yue, Ning, Lvwen, Zhang, Deju, Xie, Ni |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10687910/ https://www.ncbi.nlm.nih.gov/pubmed/38037159 http://dx.doi.org/10.1186/s40164-023-00462-7 |
Ejemplares similares
-
The multifunctional protein YB-1 potentiates PARP1 activity and decreases the efficiency of PARP1 inhibitors
por: Alemasova, Elizaveta E., et al.
Publicado: (2018) -
Phosphorylation of ribosomal protein S6 confers PARP inhibitor resistance in BRCA1-deficient cancers
por: Sun, Chong-kui, et al.
Publicado: (2014) -
YB-1 Phosphorylation at Serine 209 Inhibits Its Nuclear Translocation
por: Sogorina, Ekaterina M., et al.
Publicado: (2021) -
COMPROMISED CDK1 ACTIVITY SENSITIZES BRCA-PROFICIENT CANCERS TO PARP INHIBITION
por: Johnson, Neil, et al.
Publicado: (2011) -
Impact of oncogenic K-RAS on YB-1 phosphorylation induced by ionizing radiation
por: Toulany, Mahmoud, et al.
Publicado: (2011)